Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
USD 690 In stock
USD 990 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Click to view more


2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KellyCis83 MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;RfWlEPTB;MD6xOwKBkcLz4pEJNE4xOiEQvF2= Mn;tNlU6PjB{OEK=
SK-N-AS M1PqSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXySWdKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN M135VlI2QTZyMkiy
SK-N-ASCis24 MkHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXlendtUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> NEC0[44zPTl4MEK4Ni=>
U87 NXnQUGRIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2wMVUxKM7:TR?= MlLKOFghcA>? Mnfw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? MUOyOVc2ODJ5Mx?=
HCT116 NF7JblZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKy[opWOC53LUKuOUDPxE1? NXvBfXFtPDkEoHlCpC=> NYD5UnZrUUN3ME2xMlc{yqEEsdMgNE4zOcLizszN MV[yOVc1Pjd4Mx?=
HT-29 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXiwMlUuOi53IN88US=> MUK0POKhcMLi MUjJR|UxRTdwMtMgxtHDqDFwMEVCpO69VQ>? NGCyWWIzPTd2Nke2Ny=>
Caco2 NUfEdFdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1H1OlAvPS1{LkWg{txO NVHxNWk4PDkEoHlCpC=> M1;EfGlEPTB;Nz6yOuKhyrIEoEGuOljDqM7:TR?= MoPmNlU4PDZ5NkO=
COLO 205 NXTVOpJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWCwMlUuOi53IN88US=> MmDQOFjDqGkEoB?= NVLLXnlDUUN3ME2xMlYyyqEEsdMgNE4xOsLizszN M3LpXlI2PzR4N{[z
SW480 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPCZYkxNjVvMj61JO69VQ>? Mn;UOFjDqGkEoB?= NHLGb3hKSzVyPUSuPVLDqMLzwrCwMlM{yqEQvF2= M{PZd|I2PzR4N{[z
HEK293T NX3iZ3Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXwNU02KM7:TR?= NVuwb2pYPDkEoHlCpC=> MoDuTWM2OD1{LkSyxsDDucLiMD6wOeKh|ryP MVOyOVc1Pjd4Mx?=
Hep3B  NFqxO25HfW6ldHnvckBCe3OjeR?= M1PXWVExKM7:TR?= NWjPVJlmPDkEoHlCpC=> M4LwfZJm\HWlZYOgeIhmKGWwaHHuZ4lv\yCnZn\lZ5Qhd2ZiQl3QMVY> MWeyOVY{OzV4NB?=
Hep3B  NGr0bo5HfW6ldHnvckBCe3OjeR?= NGrCUWoxNjFvMUCg{txO M3zCW|I1KGh? NFfhUlZ{fXCycnXzd4V{KHSqZTDlfJBz\XO|aX;uJI9nKGincHPp[IlvKG2UTlG= NXT2WGRkOjV4M{O1OlQ>
HEK293 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy3OJhKSzVyPUeuNVTDqMLzwrCwMlM3yqEQvF2= NEnSUoEzPTZyM{GyNi=>
DU145 NGP4dm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTnc4l7UUN3ME2yMlI5yqEEsdMgNE4xPMLizszN M4\iO|I2PjB|MUKy
HCT15 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLBb21KSzVyPUCuPFHDqMLzwrCwMlAyyqEQvF2= MWqyOVYxOzF{Mh?=
T47D MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3leo1KSzVyPUOuNVjDqMLzwrCwMlEyyqEQvF2= NYLOR4drOjV4MEOxNlI>
SMMC-7721 Mne0SpVv[3Srb36gRZN{[Xl? MkH5OFAh|ryP M3;ofFQ5KGh? MYjEUXNQ MnG3bY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> NIjTO2YzPTV2NEO2NS=>
MDA-MB-231 M3nGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P3dlczyqCq NYXD[2dNUUN3ME2yNU4zyqEEsdMgOE4zyqEQvF2= M4XGPFI2PDh4MkG5
MCF-7 NGXPOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\GN3Y4OsLiaB?= MX7JR|UxRTFyLkpCpOKyyqB{LkJCpO69VQ>? MXyyOVQ5PjJzOR?=
Jurkat MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7oO|LDqGh? NV7kOow6UUN3ME2xMlLDqMLzwrCxMlXDqM7:TR?= NH\OVVIzPTR6NkKxPS=>
HeLa MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLYcmo4OsLiaB?= MUfJR|UxRTNwOdMgxtHDqDJwM9Mg{txO NUO2VpF7OjV2OE[yNVk>
MCF7  NUXPZodlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\nOU0yODBizszN NHnmTIQ4KGR? NVO4OXZNcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYfjR5QyOjV2N{K2NVk>
K562 NVTSNJhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PDOlczyqCq MojnTWM2OD1yLkK5xsDPxE1? M4OwNlI2Ojh{NkWz
K/VP.5 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInxUpg4OsLiaB?= MVzJR|UxRTRwOdMg{txO NVrjTJo2OjV{OEK2OVM>
SH-EP  MUTGeY5kfGmxbjDBd5NigQ>? NIfRdFczOMLizsznM41t MV2yOOKhcA>? M{W5UIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBmdmSxZ3Xuc5V{KESHUGC= NWPzZZNIOjV{NkG5PFE>
SCC25 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoSzNlTDqGh? MYHJR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? NHqy[mUzPTJ{MEeyPS=>
CAL27 NYLPXG9qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwd25zOjUEoHi= MnHaTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NIPBcIczPTJ{MEeyPS=>
FaDu NYfkfIRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzTUW9tOjUEoHi= M2L6PWlEPTB;MkWuPFnDqMLzwrCxMlE{yqEQvF2= MnzXNlUzOjB5Mkm=
SCC25 NV3kNmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi0POKhcA>? NVf4VGk3UUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> NGjUfFYzPTJ{MEeyPS=>
CAL27 M3PDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke5OFjDqGh? M1H2ZWlEPTB;MUiuNlTDqMLzwrCxMlE2yqEQvF2= NUXkO29EOjV{MkC3Nlk>
FaDu M2DjUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXBNmZXPDkEoHi= NHjZPJFKSzVyPU[uOFPDqMLzwrCxMlE{yqEQvF2= M17SeVI2OjJyN{K5
SCC25 MnL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4W2VFczyqCq M{mzWGlEPTB;OD60NeKhyrIEoEGuNVHDqM7:TR?= MXeyOVIzODd{OR?=
CAL27 M17iNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fRS|czyqCq Mn6xTWM2OD12LkK3xsDDucLiMT6xOOKh|ryP MkPTNlUzOjB5Mkm=
FaDu NFXEVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[3NuKhcA>? M4HnWmlEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= NV3xPWwxOjV{MkC3Nlk>
MCF-7 NXjTS5lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTyTWs1QMLiaNMg M1fjOGROW09? M174VWlEPTB;Nz6yxsDDucLiMD64xsDPxE1? MXmyOVIyPjN5OB?=
T-47D MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\5RodNPDkEoHlCpC=> Ml7NSG1UVw>? MYTJR|UxRTdwN9MgxtHDqDBwN9Mg{txO NX7CWG5qOjV{MU[zO|g>
MDA-MB-231 NVm2Z|VsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWq0POKhcMLi MmWzSG1UVw>? NHHw[5hKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= MlzCNlUzOTZ|N{i=
DU145 NGO1T5ZCeG:ydH;zbZMhSXO|YYm= MnTSNVAuOTByIN88US=> NUTWNlhqQCCq M1TvcGROW09? NHm4eGZqdmS3Y3XzJINmdGxiZHXheIghe2mpbnnmbYNidnSueTDpckBiKH[ncomgcI94KGOxbnPlcpRz[XSrb36= Mnv2NlUyPDl4OEG=
DU145 stem-like NX3HZ4I5SXCxcITvd4l{KEG|c3H5 MmrHNVAuOTByIN88US=> MWK4JIg> NIX4cVZFVVOR NXfBOJRScW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{TVUVI2OTR7Nkix
DU145 NYP0cotsTnWwY4Tpc44hSXO|YYm= NWC3[|dGOTBvMUCwJO69VQ>? MlPJNkBp NFvHTHZFVVOR NIX4bGNqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NW[4bHJ5OjVzNEm2PFE>
DU145 stem-like MmXwSpVv[3Srb36gRZN{[Xl? MVuxNE0yODBizszN Ml;VNkBp M2\YRWROW09? NG\6WHVqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2mxbFI2OTR7Nkix
UW228-3 M1zCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMlAyNTNyMDFOwG0> MYm0PEBp NFjNW|dFVVOR NXKxNZRXUUN3ME2wMlk6yqEQvF2= M3HVVlI2OTF7MUi1
MKL-1  NUDp[XNDTnWwY4Tpc44hSXO|YYm= M1fZZlExNTFyMECgcm0> MUW0JIQ> MV\pcoR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiTVjDMWkh\XiycnXzd4lwdg>? NFPsNHAzPTFzNke1OC=>
MCF7 EV MkHtSpVv[3Srb36gRZN{[Xl? M1vZdVExNTFyMDFOwG0> MXiy5qCKcA>? NUHPXJNTcW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NUnYNZU2OjVyOEiyNFM>
MCF 7BMI1 M3iy[2Z2dmO2aX;uJGF{e2G7 NY\2SVZYOTBvMUCwJO69VQ>? MoW3NwKBkWh? M1PJUolv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MlLsNlUxQDh{MEO=
MCF7 EV NUfNVopxTnWwY4Tpc44hSXO|YYm= MmHjNVAuOTByIN88US=> NITVZZIz6oDLaB?= M4fTZWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> Mor6NlUxQDh{MEO=
HepG2 M2G4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT1boprTE2VT9Mg MV7JR|UxRTNyLkG2xsDDucLiMD61NOKh|ryP MnXJNlUxPzh|MUG=
MOLT-3 NF;1ZlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;EUXNQyqB? M{\jdGlEPTB;MD6wOVHDqMLzwrCwMlAxOsLizszN MV:yOVA4QDNzMR?=
HT1080 NV7LNZNGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTYSnJsOS1zMECg{txO M2DNV|QwOjRxNEigbC=> NUPORZRbTE2VT9Mg MXzpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NFTZS2czPTB5OEC2OC=>
HT1080 MV7GeY5kfGmxbjDBd5NigQ>? Mkm1NE4xODBzLUGwNEDPxE1? NIPadpQyNTJ2IHi= NVXjS5NHTE2VT9Mg MlnnbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ MnnnNlUxPzhyNkS=
HT1080 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG0NE4xODBzLUGwNEDPxE1? MYSyOEBp NU\0dFAyTE2VT9Mg NVXTdlFW[2G3c3XzJIFvKGmwY4LlZZNmKGmwIITo[UBvfW2kZYKgc4Yh[2WubIOgbY4hTzJxTTyge4hqdGViZHXjdoVie2mwZzDTJIFv\CCJMTDwbIF{\SClZXzsdy=> NYLtNYI1OjVyN{iwOlQ>
HD-MY-Z MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\vTVI1NzR6L{eyJIg> Mn3yTWM2OO,:nkGwNEDPxE1? NIrCT|IzPTB2OEKzOi=>
DOHH-2 M2nQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULKOIhZOjRiaB?= M2PLdmlEPTExvK6xNFAh|ryP MoDONlUxPDh{M{[=
DOHH-2 MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULWNFl5PDhiaB?= NIfKOoJKSzVyPUG5MlnDqM7:TR?= MYCyOVA1QDJ|Nh?=
DOHH-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DtNVczKGh? NI\5NWdKSzVyPUZCpO69VQ>? NEDHZo8zPTB2OEKzOi=>
REH M1vTeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37idlQ5KGh? M4fye2lEPTB;MD6wNVTDqM7:TR?= NH;NfoczPTB2OEKzOi=>
REH MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWq3NkBp M3HaTGlEPTB;MD6wNVXDqM7:TR?= MUiyOVA1QDJ|Nh?=
HH NGX4XnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXWNlQhcA>? MoTSTWM2OD1zMESuO:Kh|ryP NXPlb|F2OjVyNEiyN|Y>
HH NHHmeWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkf1OFghcA>? MnP1TWM2OD12OD62xsDPxE1? NX32NYlIOjVyNEiyN|Y>
HH MojVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYO3NkBp M1fYZmlEPTB;MUSuO:Kh|ryP MXyyOVA1QDJ|Nh?=
HuT-78 MnG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvQNlQhcA>? MYfJR|UxRTlwM9Mg{txO NGq2SJEzPTB2OEKzOi=>
HuT-78 NGLKVIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3C[GpyPDhiaB?= MXXJR|UxRTRwM9Mg{txO NF;neIwzPTB2OEKzOi=>
HuT-78 M3LmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVW3NkBp MXjJR|UxRTRwMtMg{txO NVj5S2toOjVyNEiyN|Y>
OPM-2 NVjjNnRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XhPVI1KGh? MoHnTWM2OD1{ND6xxsDPxE1? MWKyOVA1QDJ|Nh?=
OPM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHQRlQ6PDhiaB?= MWDJR|UxRTUEoN88US=> MnLCNlUxPDh{M{[=
RPMI-8226 M3rrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHBXXIzPCCq NVPJ[2psUUN3ME2xNFYvPsLizszN MUmyOVA1QDJ|Nh?=
RPMI-8226 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX20PEBp MWjJR|UxRTlzLkJCpO69VQ>? M2X3W|I2ODR6MkO2
RPMI-8226 NUfsUGpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW3NkBp MW\JR|UxRTF2LkpCpO69VQ>? NGHmfYQzPTB2OEKzOi=>
U-266 M3;jOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X0eFI1KGh? MoDZTWM2OD16Nj6yxsDPxE1? MnXXNlUxPDh{M{[=
U-266 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWK0PEBp M2\pV2lEPTB;NkiuOOKh|ryP MWqyOVA1QDJ|Nh?=
U-266 M3fNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELUOXM4OiCq NF\uN|FKSzVyPUK3MlTDqM7:TR?= M3\oZ|I2ODR6MkO2
Kelly NWmxUYxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7nPJcxNTFyIN88US=> NX3xR4RGPzMEoHi= NX\OeXpzUUN3ME2xMlUyQMLizszN MYCyOVAxQDlyMB?=
SH-SY5Y  MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMVExKM7:TR?= Ml;LO|LDqGh? NWr1VGpoUUN3ME2wMlc2PMLizszNxsA> MYOyOVAxQDlyMB?=
SK-N-DZ NUnhcHFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zZd|AuOTBizszN NWfIfoxJPzMEoHi= NIm5ZnpKSzVyPUWuOFg2yqEQvF2= NH3MUlQzPTByOEmwNC=>
HepG2 M2LCSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTHdnk1QMLiaB?= MWPEUXNQyqB? M{XlWWlEPTB;MUOuOlXDqMLzwrCwMlkzyqEQvF2= NG\LZWIzPDl7NkGzOi=>
A549 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PobVQ5yqCq MUPEUXNQyqB? NV21VlRQUUN3ME2yOFEvQcLiwsJCpFMyNjJ|wrFOwG0> NUPwW4pVOjR7OU[xN|Y>
MCF7 MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1qwVVQ5yqCq M1fSVGROW00EoB?= MlXiTWM2OD16MT6wPeKhyrIEoEG0MlIyyqEQvF2= NXfGcIlvOjR7OU[xN|Y>
HL-60  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;sR3kyPzMEoHi= MYrJR|UxRTBwMUNihKXPxE1? NIXVUYMzPDl7M{CxOC=>
HL-60[R] M1nsU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG3NuKhcA>? NIDWRoJKSzVyPUOuNVLjiIYQvF2= MVuyOFk6OzBzNB?=
MCF-7 Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrYS2k2OD1yLkK1JOKyKDBwMTFOwG0> NYHGTnpKOjR7NUO4NlE>
MO59K  NHK5bYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYK3JIQ> M3vYUGlEPTB;MD6xO-KBjc7:TR?= Mlr0NlQ6PTN3NkG=
MO59J NGXxVpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvVO{Bl NUXCWpVTUUN3ME2wMlHjiIYQvF2= NUX3bmxsOjR7NUO1OlE>
ME 180 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PHXFQ5yqCqwrC= MVvJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? NYW2S3JyOjR7NUOwNlc>
MCF-7 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\peWxJPDkEoHlCpC=> NVXmUlNRUUN3ME2yN{46KMLzIECuN-KBjc7:TR?= MoPwNlQ6PTNyMke=
HeLa MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHmR49DPDkEoHlCpC=> Mnn1TWM2OD12LkexJOKyKDFwNPMAie69VQ>? MnPsNlQ6PTNyMke=
MDA-MB-453 M4GzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\WOFQ5yqCqwrC= NIXLSWdKSzVyPUGyMlUhyrFiMD64OgKBjc7:TR?= NWW4enFJOjR7NUOwNlc>
MDA-MB-231 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXvU2w6PDkEoHlCpC=> NETyWnlKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= MmDDNlQ6PTNyMke=
PC-3 NGnlOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0POKhcMLi M3jvUmlEPTB;MUSuOEDDuSB|LkKz5qCG|ryP Mn7wNlQ6PTNyMke=
HT-29 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfIRow1QMLiaNMg NGfkR4xKSzVyPUKxMlQ2KMLzIEOuPFfjiIYQvF2= MUCyOFk2OzB{Nx?=
BGC-823 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnvNGd2PDkEoHlCpC=> NHHhcJpKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= MkXXNlQ4QTN6N{e=
HeLa NX7Hd2RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;NOmRwPDkEoHlCpC=> MVnJR|UxRTJyOT65NEDDuSBzMz60NkDjiIYQvF2= M3S1PFI1Pzl|OEe3
A549 NICxbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO4TYhsPDkEoHlCpC=> MUfJR|UxRTF|OT61OEDDuSB5LkC15qCG|ryP M4j1ZlI1Pzl|OEe3
HK-2 M1y0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX63fXlNPDkEoHlCpC=> NIrTXHdKSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= MmqzNlQ4QTN6N{e=

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]


Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56


CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03036904 Not yet recruiting Diffuse Large B-Cell Lymphoma|High Grade B-Cell Lymphoma Weill Medical College of Cornell University|Genentech, Inc.|Massachusetts General Hospital|M.D. Anderson Cancer Center February 6, 2017 Phase 1
NCT02432274 Recruiting Tumors|Solid Malignant Tumors|Osteosarcoma|Differentiated Thyroid Cancer (DTC) Eisai Limited|Eisai Inc. December 29, 2014 Phase 1|Phase 2
NCT02385110 Recruiting Leukemia M.D. Anderson Cancer Center September 23, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03016871 Not yet recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 2
NCT03041311 Not yet recruiting Small Cell Lung Cancer G1 Therapeutics, Inc. May 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID